Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, we demonstrated that IL7 mediates an intrinsic and physiologic mechanism of GC resistance in normal thymocyte development that is retained during leukemogenesis in a subset of T-ALLs and is reversible with targeted inhibition of the IL7R/JAK/STAT5/BCL-2 axis.
|
31687977 |
2020 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found that T-ALL are hypersensitive to navitoclax, an inhibitor of BCL2 family of antiapoptotic proteins.
|
30224339 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results shed new light on the oncogenic function of ribosomal mutations in cancer, provide a novel mechanism for BCL-2 upregulation in leukemia, and highlight BCL-2 inhibition as a novel therapeutic opportunity in RPL10 R98S defective T-ALL.
|
29930300 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we evaluated the therapeutic potential of the combination of the Bcl-2 antagonist ABT-199 and cytotoxic agent gemcitabine in T-ALL cell lines.
|
30320607 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
|
30232463 |
2018 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
|
28852199 |
2018 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations.
|
29854301 |
2018 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
|
28074072 |
2017 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The BCL2-inhibitor venetoclax was highly active below 10 nM in B-cell precursor ALL (BCP-ALL) subsets, including <i>MLL</i><i>-AF4</i> and <i>TCF3-HLF</i> ALL, and in some T-cell ALLs (T-ALLs), predicting in vivo activity as a single agent and in combination with dexamethasone and vincristine.
|
28122742 |
2017 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Using human T-ALL and BaF3 cell lines with high expression levels of MEF2C, the present study tested whether the BCL2 inhibitor (ABT-737) restores the sensitivity to prednisolone (PSL), because MEF2C causes PSL resistance, possibly by augmenting the anti-apoptotic activity of BCL2.
|
26172269 |
2015 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we reveal that KLF4 induced apoptosis through the BCL2/BCLXL pathway in human T-ALL cell lines and primary T-ALL specimens.
|
25644173 |
2015 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study highlights BCL-2 as an attractive molecular target in specific subtypes of human T-ALL that could be exploited by ABT-199.
|
25301704 |
2014 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199.
|
24994123 |
2014 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Here, we use RNAi technology to identify a novel oncogenic pathway that involves aberrant activation of the TYK2 tyrosine kinase and its downstream substrate, STAT1, which ultimately promotes T-ALL cell survival through the upregulation of BCL2 expression
|
23471820 |
2013 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we use RNAi technology to identify a novel oncogenic pathway that involves aberrant activation of the TYK2 tyrosine kinase and its downstream substrate, STAT1, which ultimately promotes T-ALL cell survival through the upregulation of BCL2 expression
|
23471820 |
2013 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
On the other hand, Fbw7-deficient T-ALL cell lines are much more resistant to the Bcl-2 antagonist, ABT-737.
|
21608150 |
2011 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
zeta-Crystallin is a bcl-2 mRNA binding protein involved in bcl-2 overexpression in T-cell acute lymphocytic leukemia.
|
20103721 |
2010 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The ability of this model to detect a strong interaction between NOTCH1 and bcl2 suggests that genetic modifier screens have a high likelihood of revealing other genes that can cooperate with NOTCH1 to induce T-ALL.
|
17252014 |
2007 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The p53 mutant human T acute lymphoblastic leukemia line Jurkat transduced with the Bcl-2 gene was used as model system in vitro and in a subcutaneous transplant setting in immunodeficient mice.
|
16916556 |
2006 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Also, we have measured the levels of Bcl-2, Bcl-x, and Bax in 20 cases of T-ALL.
|
11792421 |
2002 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our data support the involvement of 2 distinct mechanisms: translocations involving LMO2, TAL2, and TAL1 in T cell acute lymphoblastic leukemia (T-ALL), are compatible with illegitimate V(D)J recombination between a TCR locus and a proto-oncogene locus bearing a fortuitous but functional recombination site (type 1); in contrast, translocations involving BCL1 and BCL2 in B cell non-Hodgkin's lymphomas (B-NHL), are compatible with a process in which only the IgH locus breaks are mediated by V(D)J recombination (type 2).
|
11781368 |
2002 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Similar to what occurs in normal immature thymocytes, prevention of spontaneous apoptosis by IL-7 in precursor T-cell acute lymphoblastic leukemia (T-ALL) cells correlates with up-regulation of bcl-2.
|
11520803 |
2001 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
For the second criterion, in B-cell ALL, p21waf1 expression at diagnosis was the sole (albeit poorly) predictive variable, whereas bcl-2 remained of high interest in T-cell ALL.
|
10848789 |
2000 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To further address the role of Bcl-2 in GC-mediated cytotoxicity, we generated subclones of the GC-sensitive human T-cell acute lymphoblastic leukemia line CCRF-CEM, in which transgenic Bcl-2 expression is regulated by tetracycline.
|
9989821 |
1999 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We have developed and validated a quantitative polymerase chain reaction (PCR) assay targeting tumor-specific chromosomal rearrangements, including del(1) involving the tal-1 locus in pediatric T-ALL and t(14;18) involving the bcl-2 locus in follicular lymphoma.
|
10233841 |
1999 |